Abbott Q3 results top estimates, keeps 2026 EPS forecast unchanged
- Abbott Laboratories press release (ABT): Q3 Non-GAAP EPS of $1.42 beats by $0.01.
- Revenue of $13.01B (+14.4% Y/Y) beats by $20M.
Reaffirmed FY2026 adjusted diluted EPS guidance of $5.50–$5.55 (vs. consensus of $5.52). FY2026 revenue consensus is $50.20B; the release did not provide revenue guidance.
GAAP diluted EPS was $0.53, compared with $0.94 a year earlier.
Diagnostics revenue rose 46.7% Y/Y to $3.31B, while comparable sales increased 6.4%.
Medical Devices revenue increased 6.9% Y/Y to $5.83B; comparable sales grew 7.8%.
Nutrition revenue rose 5.1% Y/Y to $2.26B; comparable sales increased 4.9%.
Established Pharmaceuticals revenue increased 6.8% Y/Y to $1.61B.
Recommended For You
Create Your Free Account to Keep Reading
Get the confidence to navigate an uncertain market with free breaking news and stock alerts.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.